peptide
FOXO4-DRI
emergingResearch Use OnlyInjection
Longevity peptide that selectively triggers senescent 'zombie cells' to self-destruct while sparing healthy cells. One of the most precise senolytic tools available.
Key facts
- Classification
- FOXO4-DRI is a D-retro-inverso peptide disrupting the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger selective apoptosis while sparing healthy cells.
- Primary benefits
- Longevity (9/10) · Inflammation (6/10) · Skin & Hair (4/10)
- Administration
- Injection
- Doses studied
- Dosing in humans is not well-established -- animal studies used ~5 mg/kg. Community protocols typically use much lower absolute doses. This is an experimental compound; start conservatively and consult a practitioner. Rest for 2 months between cycles.
- Evidence strength
- Emerging — 17 peer-reviewed studies
- Stacks well with
- Epithalon, GHK-Cu
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 17
- Stacks with
- 2 peptides
- Regulatory
- Research Use Only
Scientific overview
FOXO4-DRI is a D-retro-inverso peptide disrupting the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger selective apoptosis while sparing healthy cells. Demonstrated restoration of fur density, renal function, and fitness in aged mice.
Goal coverage · FOXO4-DRI
⏳ Longevity9/10
🧊 Inflammation6/10
✨ Skin & Hair4/10
Medical oversight strongly recommendedNot safe during pregnancy· 4 contraindications